Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2012 (2012), Article ID 729670, 11 pages
http://dx.doi.org/10.1155/2012/729670
Review Article

Omega-3 Fatty Acids and Vitamin D in Cardiology

1Department of Cardiology and Angiology, University Hospital Giessen, 35390 Giessen, Germany
2Department of Radiology, Bezmialem University of Istanbul, Istanbul, Turkey
3Department of Cardiology, University of Giessen, 35390 Giessen, Germany
4Department of Internal Medicine, University of Giessen, 35390 Giessen, Germany
5Department of Cardiac Surgery, University of Giessen, 35390 Giessen, Germany
6Department of Cardiovascular Surgery, University Hospital Giessen, 35390 Giessen, Germany

Received 17 April 2012; Revised 15 August 2012; Accepted 7 September 2012

Academic Editor: Hugo ten Cate

Copyright © 2012 Norbert Güttler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Mackay, I. Ford, F. Thies, S. Fielding, P. Bachoo, and J. Brittenden, “Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease,” Atherosclerosis, vol. 221, no. 514, p. 520, 2012. View at Publisher · View at Google Scholar
  2. GISSI-Prevenzione Investigators, “Dietary supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial,” The Lancet, vol. 354, no. 9177, pp. 447–455, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Reddy Vanga, M. Good, P. A. Howard, and J. L. Vacek, “Role of vitamin D in cardiovascular health,” American Journal of Cardiology, vol. 106, no. 6, pp. 798–805, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Pilz, A. Tomaschitz, E. Ritz, and T. R. Pieber, “Vitamin D status and arterial hypertension: a systematic review,” Nature Reviews, Cardiology, vol. 6, no. 10, pp. 621–630, 2009. View at Google Scholar · View at Scopus
  5. J. N. Artaza, R. Mehrotra, and K. C. Norris, “Vitamin D and the cardiovascular system,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 9, pp. 1515–1522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. H. Lee, J. H. O'Keefe, D. Bell, D. D. Hensrud, and M. F. Holick, “Vitamin D deficiency. An important, common, and easily treatable cardiovascular risk factor?” Journal of the American College of Cardiology, vol. 52, no. 24, pp. 1949–1956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Levin and Y. C. Li, “Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?” Kidney International, vol. 68, no. 5, pp. 1973–1981, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. Wu-Wong, M. Nakane, J. Ma, X. Ruan, and P. E. Kroeger, “Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells,” Atherosclerosis, vol. 186, no. 1, pp. 20–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Mozaffarian and J. H. Y. Wu, “Omega-3 fatty acids and cardiovascular disease. Effects on risk factors, molecular pathways, and clinical events,” Journal of the American College of Cardiology, vol. 58, no. 20, pp. 2047–2067, 2011. View at Google Scholar
  10. A. Leaf, J. X. Kang, Y. F. Xiao, and G. E. Billman, “Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils,” Circulation, vol. 107, no. 21, pp. 2646–2652, 2003. View at Google Scholar · View at Scopus
  11. D. B. Jump, “N-3 polyunsaturated fatty acid regulation of hepatic gene transcription,” Current Opinion in Lipidology, vol. 19, no. 3, pp. 242–247, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Adkins and D. S. Kelley, “Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids,” Journal of Nutritional Biochemistry, vol. 21, no. 9, pp. 781–792, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Rees, E. A. Miles, T. Banerjee et al., “Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men,” American Journal of Clinical Nutrition, vol. 83, no. 2, pp. 331–342, 2006. View at Google Scholar · View at Scopus
  14. I. Vedin, T. Cederholm, Y. Freund-Levi et al., “Reduced prostaglandin F2α release from blood mononuclear leukocytes after oral supplementation of ω3 fatty acids: the OmegAD study,” Journal of Lipid Research, vol. 51, no. 5, pp. 1179–1185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Arnold, A. Konkel, R. Fischer, and W. H. Schunck, “Cytochrome p450-dependent metabolism of ω-6 and ω-3 long-chain polyunsaturated fatty acids,” Pharmacological Reports, vol. 62, no. 3, pp. 536–547, 2010. View at Google Scholar · View at Scopus
  16. J. H. O'Keefe Jr., H. Abuissa, A. Sastre, D. M. Steinhaus, and W. S. Harris, “Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions,” American Journal of Cardiology, vol. 97, no. 8, pp. 1127–1130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Villa, L. Calabresi, G. Chiesa, P. Risè, C. Galli, and C. R. Sirtori, “Omega-3 fatty acid ethyl esters increase heart rate variability in patients with coronary disease,” Pharmacological Research, vol. 45, no. 6, pp. 475–478, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. J. H. Christensen, P. Gustenhoff, E. Korup et al., “Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial,” British Medical Journal, vol. 312, no. 7032, pp. 677–678, 1996. View at Google Scholar · View at Scopus
  19. J. H. Christensen and E. B. Schmidt, “n-3 fatty acids and the risk of sudden cardiac death,” Lipids, vol. 36, supplement, pp. S115–S118, 2001. View at Google Scholar · View at Scopus
  20. M. Yokoyama, H. Origasa, M. Matsuzaki et al., “Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis,” The Lancet, vol. 369, no. 9567, pp. 1090–1098, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. T. J. Wang, M. G. Larson, D. Levy et al., “Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study,” Circulation, vol. 107, no. 23, pp. 2920–2925, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. C. Heidt, M. Vician, S. K. Stracke et al., “Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study,” The Thoracic and Cardiovascular Surgeon, vol. 57, no. 5, pp. 276–280, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Nodari, M. Triggiani, U. Campia et al., “N-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study,” Circulation, vol. 124, no. 10, pp. 1100–1106, 2011. View at Publisher · View at Google Scholar
  24. B. Rauch, R. Schiele, S. Schneider et al., “OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction,” Circulation, vol. 122, no. 21, pp. 2152–2159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Kromhout, E. J. Giltay, and J. M. Geleijnse, “n-3 fatty acids and cardiovascular events after myocardial infarction,” The New England Journal of Medicine, vol. 363, no. 21, pp. 2015–2026, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. GISSI-HF investigators, “Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 372, no. 9645, pp. 1231–1239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. W. S. Harris and D. Bulchandani, “Why do omega-3 fatty acids lower serum triglycerides?” Current Opinion in Lipidology, vol. 17, no. 4, pp. 387–393, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Geleijnse, E. J. Giltay, D. E. Grobbee, A. R. T. Donders, and F. J. Kok, “Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials,” Journal of Hypertension, vol. 20, no. 8, pp. 1493–1499, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Mozaffarian, A. Geelen, I. A. Brouwer, J. M. Geleijnse, P. L. Zock, and M. B. Katan, “Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials,” Circulation, vol. 112, no. 13, pp. 1945–1952, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Kenny, D. C. Warltier, J. A. Pleuss, R. G. Hoffmann, T. L. Goodfriend, and B. M. Egan, “Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men,” American Journal of Cardiology, vol. 70, no. 15, pp. 1347–1352, 1992. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Nestel, H. Shige, S. Pomeroy, M. Cehun, M. Abbey, and D. Raederstorff, “The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans,” American Journal of Clinical Nutrition, vol. 76, no. 2, pp. 326–330, 2002. View at Google Scholar · View at Scopus
  32. C. Wang, M. Chung, A. Lichtenstein et al., “Effects of omega-3 fatty acids on cardiovascular disease,” Evidence Report/Technology Assessment (Summary), no. 94, pp. 1–8, 2004. View at Google Scholar · View at Scopus
  33. S. D. Kristensen, A. M. Bach Iversen, and E. B. Schmidt, “n-3 polyunsaturated fatty acids and coronary thrombosis,” Lipids, vol. 36, supplement, pp. S79–S82, 2001. View at Google Scholar · View at Scopus
  34. V. Schiano, E. Laurenzano, G. Brevetti et al., “Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function,” Clinical Nutrition, vol. 27, no. 2, pp. 241–247, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. G. E. Peoples, P. L. McLennan, P. R. C. Howe, and H. Groeller, “Fish oil reduces heart rate and oxygen consumption during exercise,” Journal of Cardiovascular Pharmacology, vol. 52, no. 6, pp. 540–547, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Ghio, L. Scelsi, R. Latini et al., “Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial,” European Journal of Heart Failure, vol. 12, no. 12, pp. 1345–1353, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Nodari, M. Triggiani, U. Campia et al., “Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy,” Journal of the American College of Cardiology, vol. 57, no. 7, pp. 870–879, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Hartweg, R. Perera, V. Montori, S. Dinneen, H. A. Neil, and A. Farmer, “Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003205, 2008. View at Google Scholar · View at Scopus
  39. M. James, S. Proudman, and L. Cleland, “Fish oil and rheumatoid arthritis: past, present and future,” Proceedings of the Nutrition Society, vol. 69, no. 3, pp. 316–323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. H. León, M. C. Shibata, S. Sivakumaran, M. Dorgan, T. Chatterley, and R. T. Tsuyuki, “Effect of fish oil on arrhythmias and mortality: systematic review,” British Medical Journal, vol. 337, Article ID a2931, 2008. View at Google Scholar · View at Scopus
  41. D. Weitz, H. Weintraub, E. Fisher, and A. Z. Schwartzbard, “Fish oil for the treatment of cardiovascular disease,” Cardiology in Review, vol. 18, no. 5, pp. 258–263, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. H. Lichtenstein, “Remarks on clinical data concerning dietary supplements that affect antithrombotic therapy,” Thrombosis Research, vol. 117, no. 1-2, pp. 71–73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. W. S. Harris, “Expert opinion: omega-3 fatty acids and bleeding-cause for concern?” American Journal of Cardiology, vol. 99, no. 6, supplement 1, pp. S44–S46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. H. Lichtenstein, L. J. Appel, M. Brands et al., “Diet and lifestyle recommendations revision 2006: a scientific statement from the American heart association nutrition committee,” Circulation, vol. 114, no. 1, pp. 82–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. D. M. Lloyd-Jones, Y. Hong, D. Labarthe et al., “Defining and setting national goals for cardiovascular health promotion and disease reduction: the American heart association's strategic impact goal through 2020 and beyond,” Circulation, vol. 121, no. 4, pp. 586–613, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. U.S. Department of Agriculture and U.S. Department of Health and Human Services, Dietary Guidelines For Americans, 2010, U.S. Government Printing Office, Washington, DC, USA, 7th edition, 2010.
  47. M. F. Holick, “Vitamin D deficiency,” The New England Journal of Medicine, vol. 357, pp. 266–281, 2007. View at Publisher · View at Google Scholar
  48. Y. C. Li, J. Kong, M. Wei, Z. F. Chen, S. Q. Liu, and L. P. Cao, “1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system,” Journal of Clinical Investigation, vol. 110, no. 2, pp. 229–238, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Agarwal, M. Acharya, J. Tian et al., “Antiproteinuric effect of oral paricalcitol in chronic kidney disease,” Kidney International, vol. 68, no. 6, pp. 2823–2828, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Duprez, M. de Buyzere, T. de Backer, and D. Clement, “Relationship between vitamin D3 and the peripheral circulation in moderate arterial primary hypertension,” Blood Pressure, vol. 3, no. 6, pp. 389–393, 1994. View at Google Scholar · View at Scopus
  51. E. Kristal-Boneh, P. Froom, G. Harari, and J. Ribak, “Association of calcitriol and blood pressure in normotensive men,” Hypertension, vol. 30, no. 5, pp. 1289–1294, 1997. View at Google Scholar · View at Scopus
  52. R. Scragg, I. Holdaway, V. Singh, P. Metcalf, J. Baker, and E. Dryson, “Serum 25-hydroxycholecalciferol concentration in newly detected hypertension,” American Journal of Hypertension, vol. 8, no. 4, part 1, pp. 429–432, 1995. View at Google Scholar · View at Scopus
  53. M. L. Melamed, P. Muntner, E. D. Michos et al., “Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease results from NHANES 2001 to 2004,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 6, pp. 1179–1185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Targher, L. Bertolini, R. Padovani et al., “Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients,” Clinical Endocrinology, vol. 65, no. 5, pp. 593–597, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Giovannucci, Y. Liu, B. W. Hollis, and E. B. Rimm, “25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study,” Archives of Internal Medicine, vol. 168, no. 11, pp. 1174–1180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. T. J. Wang, M. J. Pencina, S. L. Booth et al., “Vitamin D deficiency and risk of cardiovascular disease,” Circulation, vol. 117, no. 4, pp. 503–511, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Shane, D. Mancini, K. Aaronson et al., “Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure,” American Journal of Medicine, vol. 103, no. 3, pp. 197–207, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Bahrami, R. Kronmal, D. A. Bluemke et al., “Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis,” Archives of Internal Medicine, vol. 168, no. 19, pp. 2138–2145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. S. S. Coughlin, L. Myers, and R. K. Michaels, “What explains black-white differences in survival in idiopathic dilated cardiomyopathy? The Washington, DC, dilated cardiomyopathy study,” Journal of the National Medical Association, vol. 89, no. 4, pp. 277–282, 1997. View at Google Scholar · View at Scopus
  60. V. Vaccarino, E. Gahbauer, S. V. Kasl, P. A. Charpentier, D. Acampora, and H. M. Krumholz, “Differences between African Americans and whites in the outcome of heart failure: evidence for a greater functional decline in African Americans,” American Heart Journal, vol. 143, no. 6, pp. 1058–1067, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. M. E. Reusser, D. B. DiRienzo, G. D. Miller, and D. A. McCarron, “Adequate nutrient intake can reduce cardiovascular disease risk in African Americans,” Journal of the National Medical Association, vol. 95, no. 3, pp. 188–195, 2003. View at Google Scholar · View at Scopus
  62. S. Pilz, H. Dobnig, G. Nijpels et al., “Vitamin D and mortality in older men and women,” Clinical Endocrinology, vol. 71, no. 5, pp. 666–672, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. R. D. Semba, D. K. Houston, L. Ferrucci et al., “Low serum 25-hydroxyvitamin D concentrations are associated with greater all-cause mortality in older community-dwelling women,” Nutrition Research, vol. 29, no. 8, pp. 525–530, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Szulc, B. Claustrat, and P. D. Delmas, “Serum concentrations of 17β-E2 and 25-hydroxycholecalciferol (25OHD) in relation to all-cause mortality in older men—the MINOS study,” Clinical Endocrinology, vol. 71, no. 4, pp. 594–602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Autier and S. Gandini, “Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials,” Archives of Internal Medicine, vol. 167, no. 16, pp. 1730–1737, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. H. A. Bischoff-Ferrari, E. Giovannucci, W. C. Willett, T. Dietrich, and B. Dawson-Hughes, “Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes,” American Journal of Clinical Nutrition, vol. 84, no. 1, pp. 18–28, 2006. View at Google Scholar · View at Scopus
  67. Food and Nutrition Board, Dietary supplement fact sheet: vitamin D, http://ods.od.nih.gov/.
  68. J. E. Manson, S. S. Bassuk, I. M. Lee et al., “The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease,” Contemporary Clinical Trials, vol. 33, no. 1, pp. 159–171, 2012. View at Publisher · View at Google Scholar